Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Prevention of Experimental Colitis in SCID Mice Reconstituted with CD45RBhigh CD4+ T Cells by Blocking the CD40-CD154 Interactions

Zhanju Liu, Karel Geboes, Stefaan Colpaert, Lut Overbergh, Chantal Mathieu, Hubertine Heremans, Mark de Boer, Louis Boon, Geert D’Haens, Paul Rutgeerts and Jan L. Ceuppens
J Immunol June 1, 2000, 164 (11) 6005-6014; DOI: https://doi.org/10.4049/jimmunol.164.11.6005
Zhanju Liu
*Laboratory of Experimental Immunology,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karel Geboes
†Department of Pathology,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefaan Colpaert
*Laboratory of Experimental Immunology,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lut Overbergh
‡Laboratory of Experimental Transplantation, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chantal Mathieu
‡Laboratory of Experimental Transplantation, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hubertine Heremans
¶Laboratory of Immunobiology, Rega Institute, University of Leuven, Leuven, Belgium; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark de Boer
∥Tanox Pharma, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louis Boon
∥Tanox Pharma, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geert D’Haens
§Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Rutgeerts
§Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan L. Ceuppens
*Laboratory of Experimental Immunology,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Increased expression of CD40 and CD40 ligand (CD40L or CD154) has been found in inflamed mucosa of human inflammatory bowel disease (IBD), and interactions between these molecules seem to be involved in local cytokine production by macrophages. However, the precise role of CD40 signaling in the pathogenesis of IBD is still poorly understood. The aim of the present study was to investigate the in vivo relevance of CD40 signaling in experimental colitis in SCID mice reconstituted with syngeneic CD45RBhighCD4+ T cells. The results demonstrated that CD40+ and CD40L+ cells as well as their mRNA levels were significantly increased in inflamed mucosa. Administration of anti-CD40L neutralizing mAb over an 8-wk period starting immediately after CD45RBhighCD4+ T cell reconstitution completely prevented symptoms of wasting disease. Intestinal mucosal inflammation was effectively prevented, as revealed by abrogated leukocyte infiltration and decreased CD54 expression and strongly diminished mRNA levels of the proinflammatory cytokines IFN-γ, TNF, and IL-12. When colitic SCID mice were treated with anti-CD40L starting at 5 wk after T cell transfer up to 8 wk, this delayed treatment still led to significant clinical and histological improvement and down-regulated proinflammatory cytokine secretion. These data suggest that the CD40-CD40L interactions are essential for the Th1 inflammatory responses in the bowel in this experimental model of colitis. Blockade of CD40 signaling may be beneficial to human IBD.

Crohn’s disease and ulcerative colitis are two major forms of human inflammatory bowel disease (IBD).3 Their etiopathology is unknown, but increasing evidence indicates that immune mechanisms play an important role (1). These include increased T cell infiltrates in inflamed intestinal mucosa, the production of cytokines by lamina propria T cells, and remission after treatment with immunosuppressants or by targeting proinflammatory cytokines. Moreover, experimental colitis clinically mimicking human IBD can be induced in murine models by a disrupted T cell-regulatory system (1, 2). However, the initiating event for signal-mediated lymphocyte activation in the intestinal mucosa is still poorly understood.

There is increasing evidence that interactions between CD40 ligand (CD40L) expressed on activated T cells and CD40 expressed on APC play a critical role in humoral and cellular immune responses (3, 4). CD40 signaling provides a signal for B cell activation, proliferation, and Ig isotype switching. It also stimulates monocyte/macrophage activation and cytokine production and up-regulates expression of costimulatory molecules such as B7 family molecules and of MHC class II on the surface of APC. Moreover, CD40 ligation induces expression of adhesion molecules such as CD54, CD62E, and CD106 on endothelial cells, suggesting that CD40 signaling plays an important role in leukocyte extravasation to sites of inflammation (5, 6). In recent years, greater attention has been paid to the role of CD40-CD40L interactions in the immunopathogenesis of some autoimmune diseases, where T or B cells have a prominent role, such as systemic lupus erythematosus (7), rheumatoid arthritis (8), and multiple sclerosis (9) as well as in allograft rejection (10). Administration of mAb directed against CD40L has been shown to effectively inhibit inflammatory responses in a variety of animal models such as experimental allergic encephalomyelitis (9, 11), lupus nephritis (12), collagen-induced arthritis (13), atherosclerosis (14), and spontaneous autoimmune diabetes (15). This Ab also dramatically prevents murine pancreatic islet allograft rejection (16) and CD4+ T cell-mediated graft-vs-host disease and marrow allograft rejection (17). These results have led to the conclusion that CD40-CD40L interactions play a central role in the pathogenesis of several autoimmune diseases and that target treatment against CD40 signaling may lead to improvement of ongoing disease.

The role of the CD40 stimulatory pathway in intestinal immunopathology has been suggested by the effect of anti-CD40L treatment in murine colitis induced by 2,4,6-trinitrobenzenesulfonic acid (18) and by data on CD40L-transgenic mice (19). More recently, we have reported that expression of CD40 and CD40L is considerably increased in inflamed mucosa from IBD patients and that CD40L expressed on lamina propria T cells is able to induce proinflammatory cytokine production by monocytes (20). These data indicate that CD40-CD40L interactions are probably relevant to the pathogenesis of human IBD. To further analyze the role of CD40-CD40L interactions, we used an experimental murine model for colitis, which has been shown to be useful for the investigation of the pathogenesis of human IBD (21, 22, 23, 24). SCID mice are reconstituted with syngeneic CD45RBhighCD4+ T cells. These SCID recipients develop a wasting disease 6–10 wk after T cell reconstitution. The disease is characterized by diarrhea, weight loss, transmural inflammation in the proximal colon, and a Th1 immune response by lamina propria CD4+ T cells in the diseased colon. The clinical, histopathological, and immunological features resemble those observed in human Crohn’s disease (1, 2). In the present study, treatment with anti-CD40L neutralizing mAb was performed in this model to determine the role of CD40 signaling in the pathogenesis of this CD4+ T cell-mediated colitis in vivo.

Materials and Methods

Animals

Specific pathogen-free female BALB/c mice were obtained from the Harlan Company (Zeist, The Netherlands). Female BALB/c SCID mice were bred under standard pathogen-free conditions and maintained in the Animal Care Facility of the Faculty of Medicine, Gasthuisberg, Catholic University of Leuven (Leuven, Belgium). BALB/c SCID mice were raised under specific pathogen-free conditions in microisolator cages with filtered air and were fed autoclaved food and water. Mice were used at 6–8 wk of age.

Reagents and mAbs

Anti-mouse CD3ε mAb (clone 500A2, hamster IgG), biotinylated anti-mouse CD4 mAb (clone H129.19, rat IgG2a), anti-mouse CD40 mAb (clone 3/23, rat IgG2a), FITC-conjugated anti-mouse CD45RB mAb (clone 16A, rat IgG2a), and PE-conjugated anti-mouse CD4 mAb (clone GK1.5, rat IgG2b) were purchased from PharMingen (San Diego, CA). Anti-mouse CD54 (clone KAT-1, rat IgG2a) was obtained from BioSource International (Nivelles, Belgium). Biotinylated anti-mouse F4/80 mAb (clone CI:A3–1, rat IgG2b), directed specifically against a murine macrophage-restricted cell surface glycoprotein, was purchased from Serotec (Oxford, U.K.). Hamster anti-mouse CD40L mAb (clone MR1) was purified from culture supernatants of the MR1 hybridoma (25), which was obtained from the American Type Culture Collection (Manassas, VA). Hamster IgG (HIg) used as a control Ab was purchased from BioTrend (Cologne, Germany).

Isolation of CD4+ T cell subpopulations

Spleen cells from BALB/c mice were used as a source of CD4+ cells for reconstitution of SCID recipient mice. CD4+ T cells subsets from the spleen of BALB/c mice were isolated as described previously (22) with some modifications. Briefly, a single cell suspension was prepared in cold PBS from BALB/c spleen. CD4+ T cell subsets were purified by positive selection using mouse CD4 Dynabeads (L3T4) and mouse CD4 DETACHaBEAD (Dynal, Oslo, Norway). These procedures resulted in ≥98% CD4+ T cells as assessed on a FACSort (Becton Dickinson, San Jose, CA). For preparation of CD45RBhigh and CD45RBlowCD4+ T cell subsets, CD4+ T cells were labeled with FITC-conjugated anti-CD45RB and PE-conjugated anti-CD4 mAbs and fractionated into CD4+ CD45RBhigh and CD4+CD45RBlow fractions under sterile conditions by two-color sorting on a FACS Vantage (Becton Dickinson). The CD45RBhigh and CD45RBlow populations were defined as the brightest staining 40–50% and the dullest staining 15–20% CD4+ T cells, respectively. Intermediate staining populations were discarded. All populations were >99% pure on reanalysis.

Reconstitution of SCID mice with T cell subpopulations and Ab treatment

BALB/c SCID mice were injected i.p. with sorted syngeneic CD45RBhigh or CD45RBlow CD4+ T cells (4 × 105/mouse of each cell). Disease activities were monitored weekly on the basis of body weight, soft stool or diarrhea, and anorectal prolapse. SCID mice, reconstituted with CD45RBhigh T cells, were treated by i.p. injection with 250 μg anti-CD40L mAb (MR1) in 200 μl PBS twice weekly, from the beginning of T cell reconstitution over a period of 8 wk. An equivalent amount of HIg was administrated in control mice under identical conditions. Because previous work has reported loss of body weight in colitic SCID recipients starting 3–5 wk after T cell reconstitution (21, 22, 23, 24), we treated another group of SCID mice by i.p. injection with 250 μg anti-CD40L mAb in 200 μl PBS twice weekly, from 5 wk after T cell reconstitution up to wk 8, to determine the effect of delayed treatment with anti-CD40L. Mice were sacrificed 8 wk after T cell reconstitution and analyzed for bowel inflammation.

Histological examination and immunohistochemistry

Tissue samples were fixed in PBS containing 6% neutral-buffered formalin. Paraffin-embedded sections (5 μm) were stained with hematoxylin and eosin. The sections were analyzed without prior knowledge of the type of T cell reconstitution or treatment. Microscopic sections were graded by the number and severity of lesions. The mean degree of inflammation in the colon was calculated using a modification of a previously described scoring system (Table I⇓) (26).

View this table:
  • View inline
  • View popup
Table I.

Histological scoring system

Colonic samples for immunohistochemistry were embedded in OCT compound, snap-frozen in liquid nitrogen, and stored at −80°C. Cryostat sections (5 μm) of colonic tissue were fixed and stained for the presence of CD40, CD40L, CD54, CD4, and F4/80 using an avidin-biotin-peroxidase complex technique (20). Serial sections were incubated for 30 min with 5–10 μg/ml mAb directed against CD40L, CD40, or CD54. The biotinylated goat anti-hamster IgG (Jackson Immunoresearch Laboratories, West Grove, PA; 1:400) or rabbit anti-rat IgG (Dako, Glostrup, Denmark; 1:400) was chosen as second Ab. After three washes with PBS, the avidin-biotin-peroxidase complex (Dako) was added, and sections were incubated for 30 min. Staining for CD4 or F4/80 Ag was performed using biotinylated anti-CD4 or anti-F4/80 as primary Ab at a concentration of 5–10 μg/ml, followed by incubation with the avidin-biotin-peroxidase complex. The color reaction was developed with 0.05% 3-amino-9-ethylcarbazole (Janssen, Beerse, Belgium). The slides were counterstained with hematoxylin. Negative control experiments were performed by incubating sections with irrelevant isotype-matched HIg or rat IgG, or by omitting the primary Ab.

Isolation of lamina propria CD4+ T cells

Colonic samples were washed thoroughly with PBS to remove debris and blood and were cut into 0.5-cm pieces. The epithelium was removed from the lamina propria by incubation with 2 mM DTT and 1 mM EDTA in PBS at 37°C for 2 × 20 min under gentle shaking. Tissues were subsequently minced into 2- × 2-mm pieces and digested with 0.5 mg/ml collagenase A (Boehringer Mannheim, Mannheim, Germany) in 5% CO2 humidified air at 37°C for 90–120 min. Lamina propria mononuclear cells were harvested by discontinuous Percoll (Pharmacia, Uppsala, Sweden) gradients. CD4+ T cells were then purified from lamina propria mononuclear cells by positive selection using mouse CD4 Dynabeads (L3T4) and mouse CD4 DETACHaBEAD as described above. The purity of cell population was >98% CD4+ T cells as assessed on a FACSort.

Lamina propria CD4+ T cell cytokine production

Ninety-six-well culture plates (Nunc, Roskilde, Denmark) were precoated with anti-CD3ε mAb (final concentration, 5 μg/ml) in 100 μl PBS at 37°C for 4 h and washed with PBS three times to remove unbound Ab. Lamina propria CD4+ T cells (5 × 105/ml) were incubated in the presence of coated anti-CD3ε and mitomycin C-treated (50 μg/ml for 30 min at 37°C) mouse mastocytoma P815 cells transfected with mouse CD80 (5 × 106/ml) at 37°C in 5% CO2 humidified air. Samples were performed in quadruplicate in a total volume of 200 μl/well. After 48 h of culture, supernatants were harvested and assayed for IL-2, IFN-γ, and IL-4. IL-2 and IL-4 were measured by sandwich ELISA using paired matched Abs according to the manufacturer’s instructions (BioSource International). IFN-γ was determined by sandwich ELISA, as previously described (27).

RNA extraction and quantitative PCR

Colonic tissue was obtained from SCID mice either anti-CD40L-treated or control HIg-treated or unmanipulated 8 wk after of CD45RBhighCD4+ T cell reconstitution. Colonic samples from naive SCID mice and those reconstituted with CD45RBlowCD4+ T cells were also obtained as control. All colonic samples were immediately frozen in liquid nitrogen after dissection and stored at −80°C until used.

Total RNA was extracted using TRIzol reagents (Life Technologies, Gaithersburg, MD). A constant amount of 1 μg target RNA was used for cDNA synthesis. The cDNA reaction was conducted at 42°C for 80 min, using 100 U of Superscript II reverse transcriptase and 5 mM oligo(dT)16 (Life Technologies). The sequences of the primers and probes for IFN-γ, IL-4, IL-5, IL-12, TNF, and β-actin have been previously reported (28). Sense/antisense PCR primers for murine CD40 and CD40L were 5′-GTCATCTGTGGTTTAAAGTCCCG-3′/5′-AGAGAAACACCCCGAAAATGG-3′ and 5′-CTCAAACTCTGAACAGTGCGCT-3′/5′-GGCAGGTCCTAACTGACTTGCT-3′, respectively. The probes for murine CD40 and CD40L were modified to incorporate a reporter dye at the 5′-end (6-carboxyfluorescein (FAM)) and a quencher at the 3′-end (6-carboxytetramethylrhodamine (TAMRA)): 5′-FAM-AGCCCTGCTGGTCATTCCTGTCGTG-TAMRA-3′ and 5′-FAM-AGGGAAGACTGCCAGCATCAGCCCT-TAMRA-3′, respectively. All primers and probes were designed with the assistance of the computer program Primer Express and purchased from PE Applied Biosystems (Foster City, CA). Real-time quantitative PCR was performed in the ABI prism 7700 sequence detector (PE Applied Biosystems), as previously described (28). The 5′-nuclease activity of the Taq polymerase was used to cleave a nonextendable dual-labeled fluorogenic probe. Fluorescent emission was measured continuously during the PCR reaction. PCR amplifications were performed in a total volume of 25 μl containing 0.5 μl cDNA sample, 50 mM KCl, 10 mM Tris-HCl, 10 mM EDTA, 60 nM Passive Reference 1, 200 μM dNTP, 3–9 mM MgCl2, 100–200 nM concentrations of each primer, 0.625 U AmpliTaq Gold (PE Applied Biosystems), and 100 nM concentrations of the corresponding detection probe. Each PCR amplification was performed in triplicate wells using the following conditions: 50°C for 2 min and 94°C for 10 min, followed by 40 or 45 cycles at 94°C for 15 s and 60°C for 1 min. All results were normalized to β-actin to compensate for differences in the amount of cDNA in all samples.

Statistical analysis

Data were statistically analyzed by Student’s t test. p < 0.05 was considered significant.

Results

BALB/c SCID mice reconstituted with CD45RBhighCD4+ T cells develop a wasting disease with severe colitis

BALB/c SCID mice were reconstituted with either CD45RBhigh or CD45RBlowCD4+ T cells, and clinical manifestations were monitored weekly up to 8 wk. As shown in Fig. 1⇓, SCID mice that received CD45RBhighCD4+ T cells developed progressive weight loss after 3–5 wk of reconstitution. These mice had diarrhea with increased mucus in the stool, anorectal prolapse, and hunched posture by 6–8 wk. In contrast, SCID mice reconstituted with CD45RBlowCD4+ T cells appeared healthy with gradual increase of body weight and absence of diarrhea during the period of observation. Additionally, SCID mice were reconstituted with CD45RBhigh plus CD45RBlowCD4+ T cells or total CD4+ T cells (n = 8 for each group). These mice, similar to those reconstituted with CD45RBlowCD4+ T cells, showed gradual increase of body weight, and no detectable pathological changes in the intestine were seen (data not shown).

           FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

BALB/c SCID mice reconstituted with CD45RBhighCD4+ T cells develop a wasting disease. BALB/c SCID mice were reconstituted with either CD45RBhigh or CD45RBlowCD4+ T cells (4 × 105/mouse). The change of weight over an 8-wk period of observation is expressed as a percent of the original weight at the start of the experiment. Data represent the mean ± SEM of both groups from three experiments.

Macroscopically, the colon from SCID mice reconstituted with CD45RBhighCD4+ T cells was enlarged and had a greatly thickened wall. These changes were due to inflammation as shown by microscopy. Transmural inflammation was common in the ascending and transverse colon. The cellular inflammatory infiltrate was composed of large numbers of lymphocytes and macrophages mixed with a small population of neutrophils and eosinophils. Neutrophils were common in ulcerative areas (10–15% of the leukocytes) but rare in other areas (<5%), whereas monocytes/macrophages and lymphocytes were present in almost equal proportions. In the mucosa, the infiltrates showed a transmucosal distribution with diffuse basal lymphocytes. Epithelial lesions included ulceration, occasionally with a mountain-peak appearance, and less severe lesions such as mucin depletion, loss of goblet cells, and crypt abscesses (Fig. 2⇓A). In addition, architectural changes including crypt hyperplasia, crypt elongation, villous transformation of the surface, and crypt branching were regularly observed. The mucosal abnormalities were also seen in the cecum and terminal ileum. In these areas the lesions were characterized by focal aggregates of lymphocytes and macrophages in the lamina propria and by crypt hyperplasia. Splenomegaly with large amounts of lymphocytes was present in these colitic SCID mice. Moreover, infiltration of lymphocytes was commonly observed in the lamina propria and submucosa of the stomach, the periportal areas of liver, and mesenteric lymphoid nodes. In contrast, in colonic sections from CD45RBlowCD4+ T cell-reconstituted mice, only few lymphocytes and macrophages were observed in the lamina propria (Fig. 2⇓B). The mean inflammatory score was significantly higher for CD45RBhigh T cell-reconstituted mice (6.75 ± 1.75) compared with CD45RBlow T cell-reconstituted recipients (0.11 ± 0.08) (p < 0.005). In the lamina propria of the inflamed colon, the majority of CD4+ T cells displayed an activated memory phenotype with CD45RBlow and high expression of CD69 (65–76.8%) and CD25 (27.5–38.4%).

           FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

Expression of CD40 and CD40L in inflamed colon from colitic SCID mice. BALB/c SCID mice were reconstituted with T cell subpopulations as described in Fig. 1⇑. Colonic section from a CD45RBhighCD4+ T cell-reconstituted mouse showing severe inflammation, leukocyte infiltration, and ulceration (A). Colonic section from a CD45RBlowCD4+ T cell-reconstituted mouse showing little leukocyte infiltration in the lamina propria (B). Cryostat sections (5 μm) of colonic samples from colitic SCID mice were stained immunohistochemically with mAbs directed against CD40L (C) and CD40 (D), showing increased expression of CD40 and CD40L in the inflamed mucosa from colitic SCID mice. Original magnifications: A and B, ×20; C and D, ×50.

Increased expression of CD40 and CD40L in inflamed colon from SCID mice reconstituted with CD45RBhighCD4+ T cells

In situ expression of CD40 and CD40L in colonic sections was analyzed by immunohistochemistry. The number of cells expressing CD40 and CD40L was significantly increased in samples from the inflamed colon from all SCID mice reconstituted with CD45RBhighCD4+ T cells (Fig. 2⇑, C and D). The majority of positive cells were located in the lamina propria and submucosa, but some were also observed in the tunica muscularis and subserosa. The positive cells were present as a diffuse population but also in aggregates, suggesting a granulomatous type of inflammation. A membranous CD40 expression was occasionally observed in endothelial cells. No expression of CD40 and CD40L was detected in epithelial cells. In contrast, CD40 and CD40L were not or only weakly expressed in colonic sections from SCID mice reconstituted with CD45RBlow, CD45RBhigh plus CD45RBlow, or unseparated CD4+ T cells (data not shown). These findings indicate that many of the infiltrating CD4+ T cells express CD40L, whereas the majority of the infiltrating macrophages express CD40.

Early administration of anti-CD40L mAb prevents the onset and severity of experimental colitis

To study whether CD40-CD40L interactions participate in the inflammatory response in this model, we administered an anti-CD40L neutralizing mAb to SCID mice. SCID mice, reconstituted with CD45RBhighCD4+ T cells, were randomly assigned to receive either anti-CD40L neutralizing mAb or control HIg, respectively, at the dose of 250 μg/mouse by i.p. injection twice weekly starting at the time of T cell reconstitution and continuing over an 8-wk period. As shown in Fig. 3⇓A, control HIg-treated mice developed a severe colitis 6–8 wk postreconstitution, characterized by significant weight loss and diarrhea, with thickening of the colonic wall because of inflammation. Microscopic analysis of colonic sections showed transmural inflammation with high numbers of leukocytes in the lamina propria and submucosa, and prominent epithelial hyperplasia with loss of goblet cells, crypt abscesses, and extensive ulceration (Fig. 4⇓A). In contrast, anti-CD40L-treated mice appeared healthy and did not exhibit any signs of colitis, with gradual increase of body weight and absence of diarrhea. No detectable pathological changes were observed in the bowel wall (Fig. 4⇓B). The effect of anti-CD40L treatment was also illustrated by comparison of histological activity scores from colonic sections being 1.21 ± 0.42 in anti-CD40L-treated mice compared with 6.70 ± 1.24 in HIg-treated recipients (p < 0.005). A further quantitative evaluation of CD4+ T cell infiltration was provided by isolating the CD4+ T cells from the resected bowels. Only a few CD4+ T cells were recovered from the colonic tissue of anti-CD40L-treated mice as compared with those in HIg-treated mice (Table II⇓). Because the number of cells recovered from the colon of colitic SCID mice was higher than the number of cells injected i.p., these results also suggest an extensive T cell proliferation in the inflamed colon. Additionally, anti-CD40L treatment resulted in a significant reduction of splenomegaly and of the lymphocyte infiltration in the spleen (Fig. 5⇓), the liver and lymphoid nodes of SCID recipients.

           FIGURE 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3.

Effects of early and delayed anti-CD40L mAb treatment on colitis. A, Early anti-CD40L mAb treatment prevents the development of colitis in SCID mice. Colitic SCID mice were treated for 8 wk with either anti-CD40L mAb or HIg starting at the time of CD45RBhighCD4+ T cell reconstitution. B, Delayed administration of anti-CD40L mAb improves experimental colitis in colitic SCID mice. Colitic SCID mice were treated with either anti-CD40L mAb or HIg starting 5 wk after CD45RBhighCD4+ T cell reconstitution and continuing to wk 8. The change of weight over time is expressed as percent of the original weight. The arrow indicates the start of treatment. Data represent the mean ± SEM of each group from three experiments.

           FIGURE 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4.

Early anti-CD40L administration prevents intestinal mucosal inflammation and diminishes leukocyte infiltration and CD54 expression in the inflamed colon. Colonic sections from colitic SCID mice treated with either HIg (left panels) or anti-CD40L (right panels) starting at the time of CD45RBhigh T cell reconstitution up to 8 wk were stained with hematoxylin and eosin (A and B) or were stained immunohistochemically with anti-CD4 (C and D), mAb F4/80 (E and F), and anti-CD54 (G and H), respectively. Colonic sections from HIg-treated mice show severe colitis and increased numbers of CD4+, F4/80+, and CD54+ cells in lamina propria, whereas colonic sections from anti-CD40L-treated mice show normal intestinal mucosa and a few CD4+, F4/80+, and CD54+ cells in lamina propria. Original magnifications: A and B, ×50; C–H, ×150.

           FIGURE 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 5.

Anti-CD40L treatment down-regulates but does not abolish lymphocyte repopulation in the spleen of colitic SCID mice. Splenic sections from naive SCID mice (A), or colitic SCID mice given early treatment with either HIg (B) or anti-CD40L (C) were stained with hematoxylin and eosin. Splenic sections from HIg-treated mice show that lymphocytes are present in the follicles, whereas sections from anti-CD40L-treated mice demonstrate small numbers of lymphocytes in the white pulp area. Only few lymphocytes are present in the follicles from naive SCID mice. Extramedullary hemopoiesis is prominent in all animals as shown by the presence of megakaryocytes (M). Arrows indicate the white pulp area. The micrographs are representative of two different experiments with two mice per group. Original magnification, ×325.

View this table:
  • View inline
  • View popup
Table II.

Average CD4+ T cell recovery from the colon of SCID mice reconstituted with CD45RBhighCD4+ T cellsa

Colonic sections from reconstituted SCID mice treated with either anti-CD40L or HIg were stained immunohistochemically for CD4, F4/80, and CD54. As shown in Fig. 4⇑, the number of CD4+ T cells, F4/80+ macrophages, and CD54+ cells was considerably increased in the inflamed mucosa from HIg-treated mice. CD54+ cells were predominantly lymphocytes and macrophages and some were endothelial cells. In the colonic sections from anti-CD40L-treated mice, a low frequency of CD4+ T cells, F4/80+ macrophages, and CD54+ cells was found in lamina propria and submucosa, and no expression was observed in the muscularis and subserosa. These data indicate a critical role for the CD40-CD40L costimulatory pathway in the initial stage of intestinal inflammation.

Anti-CD40L improves clinical manifestations when started 4 wk after T cell reconstitution

We next evaluated whether delayed anti-CD40L treatment would improve ongoing disease. Given that our results had demonstrated that wasting disease started 3–5 wk after T cell reconstitution, and because infiltration of leukocytes and colitis were detectable from 5 wk on (data not shown), we started anti-CD40L treatment 4 wk after T cell reconstitution. Colitic SCID mice were randomly assigned to be injected i.p. with either anti-CD40L or control HIg, respectively, at the dose of 250 μg/mouse twice weekly from wk 5 after CD45RBhighCD4+ T cell reconstitution up to 8 wk. Fig. 3⇑B shows that anti-CD40L-treated mice had a significantly clinical and histological improvement with intermediate weight loss and absence of diarrhea. Histopathological analysis of colonic sections from anti-CD40L-treated mice revealed significantly diminished granulomatous inflammation, leukocyte infiltration, and epithelial hyperplasia. The inflammatory changes appeared to be focal with only mild leukocyte infiltration in the lamina propria, occasionally in the submucosa, and absence in muscular layers (data not shown). Histological scores in the colonic sections were significantly decreased in mice with delayed anti-CD40L treatment (3.75 ± 1.28) compared with those in HIg-treated mice (6.84 ± 1.44) (p < 0.05). The average CD4+ T cell recovery in the inflamed colon from delayed HIg-treated colitic SCID mouse was (1.53 ± 0.38) × 106/colon; whereas in those that received delayed anti-CD40L treatment, CD4+ T cell recovery was (0.81 ± 0.20) × 106/colon (Table II⇑).

Cytokine secretion by lamina propria CD4+ T cells

Previous work has shown that intestinal inflammation in colitic SCID mice is driven by a Th1 type of immune response with elevated levels of IFN-γ (22, 23). Because CD40-CD40L interaction plays a critical role in induction of Th1 immune responses (3, 4), we next analyzed whether production of proinflammatory cytokines was inhibited after anti-CD40L treatment. Colonic lamina propria CD4+ T cells were isolated from colitic SCID mice that had received delayed treatment with either anti-CD40L or HIg and were stimulated with coated anti-CD3ε mAb and CD80 transfectants. The levels of IL-2, IFN-γ, and IL-4 secreted in the supernatants were examined by ELISA. As shown in Fig. 6⇓, lamina propria CD4+ T cells from HIg-treated mice produced high levels of IL-2 and IFN-γ. Of particular interest, delayed administration of anti-CD40L significantly down-regulated CD4+ T cell IL-2 and IFN-γ production as compared with controls (p < 0.001). IL-4 levels were very low in all groups (data not shown). These data suggest that colonic T cells in anti-CD40L-treated mice are less preactivated in vivo or that anti-CD40L mAb binding in vivo provides a long lasting negative signal for cytokine secretion on further stimulation.

           FIGURE 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 6.

Delayed treatment with anti-CD40L decreases IL-2 and IFN-γ production by lamina propria CD4+ T cells. Lamina propria CD4+ T cells were isolated from either untreated colitic SCID mice (n = 6) or colitic SCID mice treated with anti-CD40L (n = 6) or HIg (n = 5) starting 5 wk after CD45RBhighCD4+ T cell reconstitution and continued till wk 8. These T cells (5 × 105/ml) were incubated with coated anti-CD3ε (5 μg/ml) plus CD80-transfected P815 cells (5 × 105/ml). Supernatants were harvested after 48 h of culture, and IL-2 and IFN-γ were assayed by ELISA. ∗, p < 0.005 vs controls.

Transcriptional levels of cytokines, CD40, and CD40L in colonic tissue

To further confirm that anti-CD40L treatment down-regulates proinflammatory cytokine production in the colonic tissue, we also investigated the mRNA levels of cytokines and CD40 and CD40L in colonic tissues using real-time quantitative PCR technique. As shown in Table III⇓, the mRNA levels of IFN-γ, TNF, and IL-12 p40 were greatly increased in SCID mice reconstituted with CD45RBhigh CD4+ T cells under unmanipulated or HIg-treated conditions. The mRNA levels of CD40 and CD40L were also markedly increased in inflamed colon, in agreement with immunohistochemical results. Interestingly, mRNA levels of cytokines as well as CD40 and CD40L were significantly decreased in the early anti-CD40L-treated group (p < 0.05) and they were also down-regulated in the delayed treatment group. Relatively low mRNA levels of IL-4, IL-5, and IL-10 were seen in all groups (data not shown), concurrent with earlier reports (22, 23). All cytokine mRNA levels were found to be low in colonic samples from naive SCID mice and CD45RBlow T cell-reconstituted recipients. It should be stressed that the values given for cytokine mRNA levels in Table III⇓ do not allow a quantitative comparison between the cytokines but only comparison for the same cytokine among groups of mice. These findings indicate that the CD40-CD40L costimulatory pathway plays a critical role in the induction of a Th1 response in colitic SCID mice.

View this table:
  • View inline
  • View popup
Table III.

mRNA levels of cytokines and CD40 and CD40L in the colon from SCID mice reconstituted with CD45RBhighCD4+ T cellsa

Colitis relapses after withdrawal of anti-CD40L treatment

We next explored the development of experimental colitis after withdrawal of anti-CD40L treatment. Six SCID mice were treated for 8 wk with 250 μg anti-CD40L mAb twice weekly starting immediately after CD45RBhigh CD4+ T cell reconstitution. After 8 wk, none of them had developed wasting disease (Fig. 7⇓). Three mice were sacrificed for histological examination, showing that leukocyte infiltration, granulomatous inflammation, and epithelial hyperplasia were effectively prevented. Splenomegaly was significantly reduced and some lymphocytes were observed on the splenic sections, similar to findings shown in Fig. 5⇑C. Strikingly, the remaining three mice had weight loss by 4 wk after withdrawal of anti-CD40L administration and developed severe colitis by 6–7 wk after MR1 cessation with marked loss of body weight and diarrhea (Fig. 7⇓). Anorectal prolapse was found in one of three. Macroscopically, the colon was significantly enlarged and had a thickened wall. Concurrent with this, there was an extensive leukocyte infiltrate in inflamed colon, mainly in the lamina propria and submucosa. Epithelial hyperplasia with glandular elongation was common. Ulceration was found in one colonic sample. Histological scores reached to 6.2 ± 1.1, as seen in HIg-treated recipients. These data suggest that after withdrawal of anti-CD40L and its degradation in vivo, CD4+ T cells that persist in the spleen and other organs (e.g., lymphoid nodes, liver, intestine) will be primed again by luminal Ags and expand into cytokine secreting effector cells in the intestine.

           FIGURE 7.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 7.

Colitis relapses after withdrawal of anti-CD40L treatment. Colitic SCID mice (n = 6) were treated with anti-CD40L mAb starting after CD45RBhighCD4+ T cell reconstitution and continuing over an 8-wk period. Three mice were then sacrificed for histological examination. The three remaining mice were observed for the following 7 wk, and clinical features were monitored. The arrow indicates the end of anti-CD40L treatment. Each line represents an individual mouse.

Discussion

To study the role of CD40-CD40L interactions in intestinal inflammation, we have used BALB/c SCID mice that develop a wasting disease with severe colitis after reconstitution with syngeneic CD45RBhighCD4+ T cells. The disease was characterized by weight loss, soft stools, and diarrhea; anorectal prolapse; chronic inflammatory and epithelial lesions in the colon; and a local Th1 cytokine pattern, which is in accordance with earlier studies (21, 22, 23, 24). The number of CD40+ and CD40L+ cells and their mRNA levels were significantly increased in the inflamed colon. Early administration of anti-CD40L neutralizing mAb (starting at the time of disease induction) effectively prevented the onset and progression of colitis and significantly abrogated infiltration of leukocytes (CD4+ T cells and macrophages), expression of CD54, and local proinflammatory cytokine production (e.g., IL-2, IFN-γ, IL-12, TNF) in the inflamed colon. Moreover, delayed treatment with anti-CD40L still improved clinical and histological features of ongoing CD4+ T cell-mediated colitis and down-regulated local proinflammatory cytokine secretion. Colitis relapses were observed 6–7 wk after withdrawal of anti-CD40L treatment. Our present studies on anti-CD40L treatment in an experimental colitis in SCID mice thus stress the important role of the CD40-CD40L costimulatory pathway in CD4+ T cell-dependent inflammatory responses and tissue damage in intestinal mucosa in colitic SCID mice.

Although colitis in this SCID model is clearly initiated by injection of pathogenic T cells and depends on the Th1-type cytokine secretion, this experimental colitis does not cover all pathological and symptomatic aspects of human Crohn’s disease. Genetic predisposition, persistent infection, a defective mucosal barrier and an abnormal host immune response to food Ags may all play a role in the etiology of human IBD. Crohn’s disease manifests primarily as a transmural inflammation involving the full thickness of the bowel wall that frequently leads to fissuring ulcers, fistulas, and abscess formation (29). Crohn’s disease is further characterized by the presence of typical aphthous ulcers, by transmural lymphoid hyperplasia, and by the presence of granulomas. In the present model, transmural inflammation and typical mucosal ulcers (mountain-peak ulcer) are present, whereas granulomas are not observed. Granulomas are, however, found in only 15–78% of the Crohn’s disease cases. Additionally, Crohn’s disease can be found anyplace in the gastrointestinal tract and has a predilection for the terminal ileum and ascending colon, whereas in the present model the ascending colon is predominantly involved. Crohn’s disease is also discontinuous, with areas of inflammation alternating with normal areas, and these features are also present in colitic SCID mice.

To date, there is little information on the mechanisms whereby SCID mice develop colitis after CD45RBhighCD4+ T cell reconstitution. CD45RBlowCD4+ T cells do not induce colitis, and they prevent colitis development if coadministered with CD45RBhighCD4+ T cells. CD45RBhigh (naive) CD4+ T cells, compared with CD45RBlow (memory) CD4+ T cells, produce high levels of IFN-γ and IL-2 but little IL-4 in response to primary mitogenic stimuli (30). The CD45RBlow cells on the other hand produce IL-10, and the latter is responsible for control of the disease if both subsets are coadministered (31). Increased infiltration of CD62L, CD69, αE integrin, and mucosal addressin cell adhesion molecule-1 has also been found in inflamed colon (24, 26). Wasting disease in this model can be abrogated after reducing the intestinal bacterial flora (24, 26). Bacterial Ag-activated CD4+ T cells from spontaneous colitic C3H/HeJBir mice, showing a Th1 phenotype of immune response, induce colitis after transfer into SCID mice (32). Thus, luminal bacterial Ags are the potential triggers of the inflammatory response in the SCID model, although it is not currently defined as to how these Ags trigger the initial CD4+ T cell activation and expansion. A role for intestinal Ags is also suggested by the absence or amelioration of intestinal inflammation in several knockout and transgenic models of IBD raised under completely germfree conditions (33, 34, 35).

To obtain more insight into disease pathogenesis, we analyzed the phenotypic features of lamina propria CD4+ T cells and macrophages in the inflamed colon. The majority of CD4+ T cells were CD45RBlow cells, and they expressed high levels of CD25 and CD69, indicating that these CD4+ T cells were activated memory cells. We have also found increased expression of B7.1 and B7.2 molecules by immunohistochemistry in the inflamed colon (our unpublished data), although their role in the intestinal immunopathology is currently unknown. CD54 and B7 family molecules may play a role in ensuring sustained activation of Ag-primed CD4+ T cells (36, 37, 38). As evidenced by quantitative mRNA analysis, CD4+ T cells and macrophages secrete large amounts of proinflammatory cytokines such as IFN-γ, TNF, and IL-12. IL-12 plays a critical role in the generation of Th1 immune response (39, 40). TNF has an important role in recruitment of inflammatory cells, partly by up-regulation of adhesion molecules on endothelial cells. The effects of IFN-γ, TNF, and IL-12 have been considered to be central to the pathogenesis in most animal models of experimental colitis, as well as in patients with Crohn’s disease (1). Treatment targeted against these proinflammatory cytokines has been found to effectively prevent intestinal inflammation in experimental models of colitis and (at least for TNF) also in patients with Crohn’s disease (22, 23, 41, 42). Some reports have shown that treatment targeted against IFN-γ, TNF, or mucosal addressin cell adhesion molecule-1 can decrease homing of leukocytes into the intestine and ameliorate wasting disease in these SCID recipients (22, 23, 26).

Most importantly, we found increased expression of CD40 and CD40L (by immunohistochemistry and PCR) in the colitis lesions. Early anti-CD40L treatment significantly decreased mRNA levels for the proinflammatory cytokines IFN-γ and TNF. Moreover, IL-12 p40 mRNA, which is abundant in infiltrates in inflamed colonic tissue, was effectively diminished after anti-CD40L treatment. These results were consistent with previous reports demonstrating that anti-CD40L administration inhibited Th1-driven inflammatory responses by reducing IL-12 production (11, 17, 18). Increased IL-12 production by mucosal macrophages or dendritic cells triggered by CD40 signaling can favor maturation of Th1 cells and development of cell-mediated immunity in the inflamed colon. CD40-CD40L interactions are indeed known to play a critical role in the induction of Th1 immune responses. Both CD40L transfectants and CD40L+ Th1 clones induce TNF and IL-12 secretion by CD40-expressing monocytes/macrophages in vitro (43, 44), whereas activated T cells and a Th1 clone derived from CD40L-deficient mice fail to induce IL-12 and TNF production (44, 45). CD40L-deficient mice not only show a defect in Ag-specific CD4+ T cell priming characteristic of a dramatic reduction of IFN-γ and IL-4 production (46) but also demonstrate markedly impaired production of TNF, nitric oxide, and IL-12, correlating with impaired cell-mediated immune responses against an intracellular parasite (e.g., Leishmania major) and enhanced susceptibility to infection (47, 48).

Our data thus underline the critical role of CD40 signaling in the intestinal immune pathology in this model at several levels. Anti-CD40L may prevent T-APC interactions so that T cells receive inadequate signals from residual host APC. Moreover, it can abrogate Th1 differentiation and effector function by blocking IL-12 production. Finally, anti-CD40L diminishes emigration of leukocytes at sites of inflammation in the intestine at least partly as a result of down-regulated TNF production, resulting in turn in decreased expression of CD54 on endothelial cells.

Delayed treatment with anti-CD40L also improved experimental colitis and inhibited local Th1 cytokine production, although to a lesser extent than when started immediately after T cell reconstitution. This suggests that the maintenance of intestinal inflammation requires continuous or repeated CD40-CD40L interactions and continuous T cell activity. Similar results have also demonstrated the effectiveness of anti-CD40L at advanced stages of other experimental diseases such as murine experimental allergic encephalomyelitis (9, 11) and murine lupus (12). However, no response to administration of anti-CD40L mAb was seen in established experimental diseases such as spontaneous autoimmune diabetes in nonobese diabetic mice (15) and murine colitis induced by 2,4,6-trinitrobenzenesulfonic acid (18). There is no clear explanation yet for the difference in efficacy of anti-CD40L treatment in the development and maintenance of experimental diseases. For effective inhibition of Th1-mediated inflammatory responses at the advanced stage of disease in colitic SCID mice, it is reasonable to perform further studies using increased doses of anti-CD40L mAb or combined treatments with mAb to other important player in the immune and inflammatory response.

Colitis relapses were observed 6–7 wk after withdrawal of anti-CD40L, this period of colitis relapse being similar to the time needed for colitis induction in naive SCID mice reconstituted with CD45RBhighCD4+ T cells. Histological analysis revealed persistent presence of low numbers of CD4+ T cells in the spleen and the lymphoid nodes as well as in colonic mucosa despite anti-CD40L treatment. It is likely that after withdrawal of anti-CD40L, CD4+ T cells that persisted in the spleen or other organs (e.g., liver, lymphoid nodes) are again being transported to the colonic mucosa by the bloodstream. Therefore, one must accept that the initial stimulus that triggers lamina propria CD4+ T cell activation and proliferation and induces expression of CD40L is permanently present. CD4+ T cells are then activated by luminal Ags, expand into effector cells, and induce inflammation in the colon in a CD40-CD40L-dependent way. Whether anti-CD40L treatment in the mean time acts directly by interfering with T cell homing to the colon, by interfering with T cell-dependent macrophage activation and cytokine secretion, and/or by interfering with T cell expansion, is unclear at this moment. In view of disease recurrence after treatment has been stopped, it is, however, excluded that Ag-responsive T cells were pushed into apoptosis after interaction with Ags and anti-CD40L, as has recently been shown to occur in monkeys treated with anti-CD40L mAb 5C8 after organ transplantation (49).

A hypothetical mechanism that governs the intestinal pathology in colitic SCID mice can now be proposed. After CD45RBhighCD4+ T cells migrate into the intestine, they are activated due to continuous exposure to dietary and microbial products, or possibly by intraluminal Ags presented by APC such as macrophages, dendritic cells, and perhaps epithelial cells in the intestinal mucosa. This event results in expression of CD40L. Interaction of CD40L on activated CD4+ T cells with CD40 on macrophages induces IL-12 secretion and initiates a proinflammatory cascade that includes a Th1 immune response (i.e., IFN-γ) and macrophage cytokine secretion (i.e., TNF), which amplify inflammatory responses. Furthermore, CD40-CD40L interactions also induce expression of costimulatory molecules such as B7 family molecules on macrophages/dendritic cells to amplify immune responses, as well as expression of adhesion molecules such as CD54 and mucosal addressin cell adhesion molecule-1 (26) on endothelial cells to enhance leukocyte infiltration in the inflammatory sites.

This work may have important implications in understanding initiation of intestinal immunopathology and progression of established disease. Our studies also provide evidence for the potential use of anti-CD40L immunotherapy for human IBD, especially in newly diagnosed patients or in the early stages of disease flare-up.

Acknowledgments

We thank Dr. J. Plum (University of Gent, Gent, Belgium) for his help in cell sorting on a FACS Vantage.

Footnotes

  • ↵1 This work was supported by Grants G0169.96 and G0247.98 from the Foundation for Scientific Research Flanders and Grant OT98/26 from the Onderzoeksfonds of the Catholic University of Leuven.

  • ↵2 Address correspondence and reprint requests to Dr. Jan L. Ceuppens, Laboratory of Experimental Immunology, U.Z. Gasthuisberg, University of Leuven, Herestraat 49, B-3000 Leuven, Belgium. E-mail address: Jan.Ceuppens{at}med.kuleuven.ac.be

  • ↵3 Abbreviations used in this paper: IBD, inflammatory bowel disease; CD40L, CD40 ligand; HIg, hamster IgG; FAM, 6-carboxyfluorescein; TAMRA, 6-carboxytetramethylrhodamine.

  • Received December 8, 1999.
  • Accepted March 13, 2000.
  • Copyright © 2000 by The American Association of Immunologists

References

  1. ↵
    Fiocchi, C.. 1998. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115: 182
    OpenUrlCrossRefPubMed
  2. ↵
    Powrie, F.. 1995. T cells in inflammatory bowel disease: protective and pathogenic role. Immunity 3: 171
    OpenUrlCrossRefPubMed
  3. ↵
    Foy, T. M., A. Aruffo, J. Bajorath, J. E. Buhlmann, R. J. Noelle. 1996. Immune regulation by CD40 and its ligand gp39. Annu. Rev. Immunol. 14: 591
    OpenUrlCrossRefPubMed
  4. ↵
    Grewal, I. S., R. A. Flavell. 1998. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16: 111
    OpenUrlCrossRefPubMed
  5. ↵
    Stout, R. D., J. Suttles. 1996. The many roles of CD40 in cell-mediated inflammatory responses. Immunol. Today 17: 487
    OpenUrlCrossRefPubMed
  6. ↵
    Henn, V., J. R. Slupsky, M. Grafe, I. Anagnostopoulos, R. Forster, G. Muller-Berghaus, R. A. Kroczek. 1998. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391: 591
    OpenUrlCrossRefPubMed
  7. ↵
    Desai-Mehta, A., L. Lu, R. Ramsey-Goldman, S. K. Datta. 1996. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J. Clin. Invest. 97: 2063
    OpenUrlCrossRefPubMed
  8. ↵
    MacDonald, K. P. A., Y. Nishioka, P. E. Lipsky, R. Thomas. 1997. Functional CD40 ligand is expressed by T cells in rheumatoid arthritis. J. Clin. Invest. 100: 2404
    OpenUrlCrossRefPubMed
  9. ↵
    Gerritse, K., J. D. Laman, R. J. Noelle, A. Aruffo, J. A. Ledbetter, W. J. A. Boersma, E. Claassen. 1996. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. USA 93: 2499
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Reul, R. M., J. C. Fang, M. D. Denton, C. Geehan, C. Long, R. N. Mitchell, P. Ganz, D. M. Briscoe. 1997. CD40 and CD40 ligand (CD154) are coexpressed on microvessels in vivo in human cardiac allograft rejection. Transplantation 64: 1765
    OpenUrlCrossRefPubMed
  11. ↵
    Howard, L. M., A. J. Miga, C. L. Vanderlugt, M. C. Dal Canto, J. D. Laman, R. J. Noelle, S. D. Miller. 1999. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J. Clin. Invest. 103: 281
    OpenUrlCrossRefPubMed
  12. ↵
    Kalled, S. L., A. H. Cutler, S. K. Datta, D. W. Thomas. 1998. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J. Immunol. 160: 2158
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Durie, F. H., R. A. Fava, T. M. Foy, A. Aruffo, J. A. Ledbetter, R. J. Noelle. 1993. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 261: 1328
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Mach, F., U. Schonbeck, G. K. Sukhova, E. Atkinson, P. Libby. 1998. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394: 200
    OpenUrlCrossRefPubMed
  15. ↵
    Balasa, B., T. Krahl, G. Patstone, J. Lee, R. Tisch, H. O. McDevitt, N. Sarvetnick. 1997. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetis in nonobese diabetic mice. J. Immunol. 159: 4620
    OpenUrlAbstract
  16. ↵
    Parker, D. C., D. L. Greiner, N. E. Phillips, M. C. Appel, A. W. Steele, F. H. Durie, R. J. Noelle, J. P. Mordes, A. A. Rossini. 1995. Survival of mouse pancreatic islet allograft in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc. Natl. Acad. Sci. USA 92: 9560
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Blazar, B. R., P. A. Taylor, A. Panoskaltsis-Mortari, J. Buhlman, J. Xu, R. A. Flavell, R. Korngold, R. Noelle, D. A. Vallera. 1997. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J. Immunol. 158: 29
    OpenUrlAbstract
  18. ↵
    Stüber, E., W. Strober, M. Neurath. 1996. Blocking the CD40L-CD40 in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J. Exp. Med. 183: 693
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Clegg, C. H., J. T. Rulffes, H. S. Haugen, I. H. Hoggatt, A. Aruffo, S. K. Durham, A. G. Farr, D. Hollenbaugh. 1997. Thymus dysfunction and chronic inflammatory disease in gp39 transgenic mice. Int. Immunol. 9: 1111
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Liu, Z., S. Colpaert, G. R. D’Haens, A. Kasran, M. de Boer, P. Rutgeerts, K. Geboes, J. Ceuppens. 1999. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. J. Immunol. 163: 4049
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Morrissey, P. J., K. Charrier, S. Braddy, D. Liggit, J. D. Watson. 1993. CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred in congenic severe combined immunodeficient mice: disease development is prevented by cotransfer of purified CD4+ T cells. J. Exp. Med. 178: 237
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Powrie, F., M. W. Leach, S. Mauze, S. Menon, L. B. Caddle, R. L. Coffman. 1994. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhiCD4+ T cells. Immunity 1: 553
    OpenUrlCrossRefPubMed
  23. ↵
    Powrie, F., R. Correa-Oliveira, S. Mauze, R. L. Coffman. 1994. Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J. Exp. Med. 179: 589
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Aranda, R., B. C. Sydora, P. L. McAllister, S. W. Binder, H. Y. Yang, S. Targan, M. Kronenberg. 1997. Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients. J. Immunol. 158: 3464
    OpenUrlAbstract
  25. ↵
    Noelle, R. J., M. Roy, D. M. Shepherd, I. Stamenkovic, J. A. Ledbetter, A. Aruffo. 1992. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc. Natl. Acad. Sci. USA 89: 6550
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Picarella, D., P. Hurlbut, J. Rottman, X. Shi, E. Butcher, D. J. Ringler. 1997. Monoclonal antibodies specific for β7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. J. Immunol. 158: 2099
    OpenUrlAbstract
  27. ↵
    Dijkmans, R., E. Martens, E. Beuken, F. Cornette, C. Dillen, H. Heremans, D. Boraschi, A. Billiau. 1991. Murine interferon-γ/interleukin-1 fusion protein used as antigens for the generation of hybridomas producing monoclonal anti-interleukin-1 antibodies. Cytokine 3: 134
    OpenUrlCrossRefPubMed
  28. ↵
    Overbergh, L. D., M. Waer Valckx, C. Mathieu. 1999. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptases PCR. Cytokine 11: 305
    OpenUrlCrossRefPubMed
  29. ↵
    Jenkins, D., M. Balsitis, S. Gallivan, M. F. Dixion, H. M. Gilmour, N. A. Shepherd, A. Theoodossi, G. T. Williams. 1997. Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease: The British Society of Gastroenterology Initiative. J. Clin. Pathol. 50: 93
    OpenUrlFREE Full Text
  30. ↵
    Lee, W. T., X. Yin, E. S. Vitetta. 1990. Functional and ontogenetic analysis of murine CD45Rhi and CD45Rlo CD4+ T cells. J. Immunol. 144: 3288
    OpenUrlAbstract
  31. ↵
    Asseman, C., S. Mauze, M. W. Leach, R. L. Coffman, F. Powrie. 1999. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 190: 995
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Cong, Y., S. L. Brandwein, R. P. McCabe, A. Lazenby, E. H. Birkenmeier, J. P. Sundberg, C. O. Elson. 1998. CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitis C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J. Exp. Med. 187: 855
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Sadlack, B. H., H. Merz, A. Schorle, A. C. Feller Schimpl, I. Horak. 1993. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75: 253
    OpenUrlCrossRefPubMed
  34. ↵
    Kuhn, R., J. Lohler, D. Rennick, K. Rajewsky, W. Muller. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263
    OpenUrlCrossRefPubMed
  35. ↵
    Taurog, J. D., J. A. Richardson, J. T. Croft, W. A. Simmons, M. Zhou, J. L. Fernández-Sueiro, E. Balish, R. E. Hammer. 1994. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J. Exp. Med. 180: 2359
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Damle, N. K., K. Klussman, P. S. Linsley, A. Aruffo. 1992. Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes. J. Immunol. 148: 1985
    OpenUrlAbstract
  37. ↵
    Yang, Y., J. M. Wilson. 1996. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science 273: 1862
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Grewal, I. S., H. G. Foellmer, K. D. Grewal, J. Xu, F. Hardardottir, J. L. Baron, C. A. Janeway, Jr, R. A. Flavell. 1996. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science 273: 1864
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Trinchieri, G.. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13: 251
    OpenUrlCrossRefPubMed
  40. ↵
    Gately, M. K., L. M. Renzett, J. Magram, A. S. Stern, L. Adorini, U. Gubler, D. H. Presky. 1998. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune response. Annu. Rev. Immunol. 16: 495
    OpenUrlCrossRefPubMed
  41. ↵
    Neurath, M. F., I. Fuss, B. L. Kelsall, E. Stüber, W. Strober. 1995. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182: 1281
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Targan, S. R., S. B. Hanauer, S. J. H. van Deventer, L. Mayer, D. H. Present, T. Braakman, K. L. DeWoody, T. F. Schaible, P. J. Rutgeerts. 1997. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N. Engl. J. Med. 337: 1029
    OpenUrlCrossRefPubMed
  43. ↵
    Alderson, M. R., R. J. Armitage, T. W. Tough, L. Strockbine, W. C. Fanslow, M. K. Spriggs. 1993. CD40 expression by monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J. Exp. Med. 178: 669
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Kato, T. R., H. Yamane Hakamada, H. Nariuchi. 1996. Induction of IL-12 p40 messenger RNA expression and IL-12 production of macrophages via CD40-CD40 ligand interaction. J. Immunol. 156: 3932
    OpenUrlAbstract
  45. ↵
    Stout, R. D., J. Suttles, J. Xu, I. S. Grewal, R. A. Flavell. 1996. Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. J. Immunol. 156: 8
    OpenUrlAbstract
  46. ↵
    Grewal, I. S., J. Xu, R. A. Flavell. 1995. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 378: 617
    OpenUrlCrossRefPubMed
  47. ↵
    Soong, L., J. C. Xu, I. S. Grewal, P. Kima, J. Sun, B. J. Longley, Jr, N. H. Ruddle, D. McMahon-Pratt, R. A. Flavell. 1996. Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. Immunity 4: 263
    OpenUrlCrossRefPubMed
  48. ↵
    Campbell, K. A., P. J. Ovendale, M. K. Kennedy, W. C. Fanslow, S. G. Reed, C. R. Maliszewski. 1996. CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity 4: 283
    OpenUrlCrossRefPubMed
  49. ↵
    Kirk, A. D., L. C. Burkly, D. S. Batty, R. E. Baumgartner, J. D. Berning, K. Buchanan, J. H. Fechner, Jr, R. L. Germond, R. L. Kampen, N. B. Patterson, et al 1999. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. 5: 686
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Immunology: 164 (11)
The Journal of Immunology
Vol. 164, Issue 11
1 Jun 2000
  • Table of Contents
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prevention of Experimental Colitis in SCID Mice Reconstituted with CD45RBhigh CD4+ T Cells by Blocking the CD40-CD154 Interactions
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Prevention of Experimental Colitis in SCID Mice Reconstituted with CD45RBhigh CD4+ T Cells by Blocking the CD40-CD154 Interactions
Zhanju Liu, Karel Geboes, Stefaan Colpaert, Lut Overbergh, Chantal Mathieu, Hubertine Heremans, Mark de Boer, Louis Boon, Geert D’Haens, Paul Rutgeerts, Jan L. Ceuppens
The Journal of Immunology June 1, 2000, 164 (11) 6005-6014; DOI: 10.4049/jimmunol.164.11.6005

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Prevention of Experimental Colitis in SCID Mice Reconstituted with CD45RBhigh CD4+ T Cells by Blocking the CD40-CD154 Interactions
Zhanju Liu, Karel Geboes, Stefaan Colpaert, Lut Overbergh, Chantal Mathieu, Hubertine Heremans, Mark de Boer, Louis Boon, Geert D’Haens, Paul Rutgeerts, Jan L. Ceuppens
The Journal of Immunology June 1, 2000, 164 (11) 6005-6014; DOI: 10.4049/jimmunol.164.11.6005
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Antigen presentation by dendritic cells in the aortic wall triggers T helper immune responses in atherosclerosis (54.16)
  • Eph receptors are involved in the pro-inflammatory response following spinal cord injury (54.21)
  • Liver sinusoidal endothelial cells undergo apoptosis during sepsis, leading to organ dysfunction. (54.13)
Show more INFLAMMATION

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2022 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606